Agentic AI in Manufacturing: Safe Use Cases, Controls, and Human-in-the-Loop Designs

In pharma, AI cannot simply take over processes that affect product quality, patient safety, batch release, or compliance. The safer path is staged adoption with defined context of use, strong data governance, clear action limits, and human accountability. FDA has already explored this topic through its Artificial Intelligence in Drug Manufacturing discussion paper. In parallel, the European framework for computerized systems and broader AI governance expectations underline the need for risk-based control and lifecycle oversight.

What Agentic AI in Manufacturing Means

Agentic AI in manufacturing refers to AI systems that can pursue goals across multiple steps. Instead of only answering a question or generating a report, an AI agent may monitor a workflow, identify an exception, retrieve supporting data, recommend an action, draft a ticket, update a dashboard, or trigger a predefined workflow.

In pharma manufacturing, this could mean an AI agent that reviews production schedule changes, checks material availability, flags potential batch delay risk, and prepares a recommended response for a planner. It could also support deviation triage by collecting evidence from MES, LIMS, QMS, and historian systems before a quality reviewer makes the decision.

The key difference is autonomy. Traditional automation and RPA follow predefined rules. Agentic AI can adapt its next step based on context. That is why agentic AI in manufacturing must be governed with clear boundaries, monitored outputs, and human approval points.

Safe Use Cases for Agentic AI in Manufacturing

The safest starting point is not batch release, quality disposition, or direct process control. The best starting point is operational support, where agentic AI improves speed and consistency while humans remain accountable.

EU GMP Annex 11 makes the principle especially clear for computerized systems: when systems replace manual operations, there should be no decrease in product quality, process control, or quality assurance, and no increase in overall process risk.

Controls for Safe Agentic AI in Manufacturing

Safe deployment depends on controls that make the system traceable, limited, monitored, and reversible. The NIST AI Risk Management Framework uses the functions Govern, Map, Measure, and Manage to structure AI risk management, and it highlights trustworthy AI characteristics such as validity, reliability, safety, security, resilience, accountability, transparency, and explainability.

Minimum control set

For pharma operations, these controls should connect to existing validation, change control, deviation, and quality risk management processes. FDA’s broader AI publications and drug-development good AI practice materials reinforce the importance of lifecycle management, context of use, and ongoing performance evaluation. See FDA’s AI publications page and its AI resources for drug development for related materials.

Human-in-the-Loop Designs for Pharma Operations

Human-in-the-loop design means people remain part of the workflow at the right risk points. It does not mean humans review everything. It means review and approval are placed where they protect quality, safety, and accountability.

Three levels of human involvement

In pharma manufacturing, human-approved design is essential for regulated decisions. Annex 11 also emphasizes clearly defined roles and responsibilities among process owners, system owners, qualified persons, and IT. This becomes even more important when agentic AI crosses functions.

Implementation Roadmap for Agentic AI in Manufacturing

The practical path to agentic AI in manufacturing starts before AI. First, stabilize workflows with RPA, system integration, standard operating procedures, and clean data. Then introduce agentic AI into well-understood processes.

90-day roadmap

Metrics to track

• Cycle time reduction
• First-pass recommendation acceptance
• Human override rate
• Data completeness rate
• Exception rate
• Escalation rate
• Audit trail completeness

The EU AI Act also follows a risk-based approach, including categories such as prohibited risk, high risk, transparency obligations, and minimal risk. For companies operating in Europe, this reinforces the importance of classifying agentic AI use cases before scaling them.

Conclusion

Agentic AI in manufacturing can help pharma companies move faster, reduce manual work, and improve operational response. But the safest path is not full autonomy on day one. The right path is staged adoption: start with advisory use cases, add workflow support, keep human approval for regulated decisions, and build controls around data, access, audit trails, monitoring, and rollback.

For pharma manufacturers, the winning model is not AI replaces people. It is AI supports people inside a controlled operating model.